Tetraphase Pharmaceuticals, the maker of eravacycline (Xerava), has entered into definitive agreements with Armistice Capital and others for investments worth $17.5 million from a registered direct offering and concurrent private placement.
Armistice, a health care institutional investor, will purchase 1,270,000 shares of common stock and accompanying warrants to purchase an aggregate of 1,270,000 shares of common stock, and prefunded warrants to purchase up to an aggregate of 2,063,334 shares